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Development of the Nanobody display technology to target
lentiviral vectors to antigen-presenting cells
C Goyvaerts1, K De Groeve2,3, J Dingemans2,3, S Van Lint1, L Robays1, C Heirman1, J Reiser4, X-Y Zhang5, K Thielemans1,
P De Baetselier2,3, G Raes2,3 and K Breckpot1
Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a
variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to speciﬁcally transduce APCs is required to
promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic
cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-speciﬁc
Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs,
we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover,
this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived
DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs
targeted to speciﬁc cell types.
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BACKGROUND
Dendritic cells (DCs) and macrophages are imperative for the
activation of antigen-speciﬁc T cells.1,2 Consequently, these
antigen-presenting cells (APCs) have been studied as targets in
immunotherapeutic strategies for the treatment of cancer and
infectious diseases. Numerous strategies for antigen delivery to
APCs have been developed.3 Of these, lentiviral vectors (LVs) are
particularly appealing, as LVs can accommodate large gene
inserts, provide long-term expression and deliver foreign genes
to dividing as well as non-dividing cells.4 The latter characteristic
makes them exceptionally interesting for transduction of termin-
ally differentiated cells, such as DCs.4 Several publications have
reported on the in vitro transduction of DCs with high efﬁciency
and little to no toxicity. It was moreover demonstrated that these
DCs retain their maturation potential and induce therapeutic
immune responses.5 In addition, LVs have been evaluated as an
off-the-shelf vaccine, demonstrating that LVs deliver their cargo to
DCs, simultaneously activating DCs through pathogen recognition
receptors, such as protein kinase R6,7 and Toll-like receptors,8 - 11
upon which the transduced DCs migrate to lymphoid
organs where they stimulate strong antigen-speciﬁc immune
responses.12 - 14
Despite their extensive pre-clinical use, translation of LVs to the
clinic is still in its early days.15 Engineering LVs targeted to APCs
will advance the translation of LVs from bench to bedside. Several
groups are actively working on strategies to facilitate LV
transduction to speciﬁc immune cells by replacing the commonly
used VSV envelope glycoprotein by a cell-speciﬁc alternative. An
example is the use of the measles virus H- and F-proteins to direct
LVs to B and T lymphocytes.16 - 19 With regard to APC-speciﬁc
transductional targeting, the use of MHC II-speciﬁc single-chain
antibodies (scFv) has been extensively studied. Some examples
are: (1) N-terminal insertion of a MHC II-speciﬁc scFv peptide into
VSV.G,20 (2) fusion of an MHC II-speciﬁc scFv to an amphotropic
murine leukemia virus glycoprotein21 and (3) a chimeric measles
virus H-protein, which is mutated for binding to hemagglutinin,
but incorporates a MHC II-speciﬁc scFv.22 However, the use of
chimeric glycoproteins often has a negative effect on the LV
stability and/or transduction efﬁciency. An alternative strategy to
target APCs was proposed by the group of Yang et al.23 who
targeted the DC-speciﬁc molecule DC-SIGN by the use of an
engineered Sindbis virus glycoprotein.23 Despite these efforts, it
remains difﬁcult to develop LVs that allow transduction of speciﬁc
APC subsets, without hampering their stability. Recently, an
elegant approach was proposed to improve the speciﬁcity of
retroviral vectors.24 Herein, the natural budding mechanism of
retroviruses is exploited to incorporate speciﬁc molecules in the
viral surface. Consequently, these determine the retroviral tropism.
Chandrashekran et al.24 demonstrated that retroviral vectors,
produced in an ecotropic producer cell line that over-expresses
stem cell factor on its cell membrane, were able to preferentially
transduce c-kit-expressing human stem cells. Yang et al.25 further
demonstrated that this approach can also be applied for LVs, in
this case using an anti-CD20 antibody to mediate speciﬁc
transduction of B cells. As molecular cloning of classic antibodies
or fragments offers serious challenges, alternatives have been
explored. One of them is the use of antibodies generated by
members of the Camelidae (that is, dromedaries, camels and
llamas), which produce a unique class of antibodies composed of
two identical heavy chains as opposed to the conventional (four-
chain) antibody repertoire.26 The antigen-binding part of the
molecule is composed of only one single variable region, termed
camelid heavy chain antibody VH or Nanobody (Nb). These Nbs
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offer many advantages.27 First, although Nbs can be in vivo
matured through immunization and share the high-binding
afﬁnity and speciﬁcity of antibodies, their single-domain nature
allows easy cloning and selection of antigen-speciﬁc Nbs and
drastically reduces the required size of the library that needs to be
constructed and screened. Second, the recombinant nature of Nbs
allows interesting possibilities at the level of molecular biological
manipulations, such as sequence modiﬁcation, transfer of the
antigen speciﬁcity and afﬁnity from one Nb to another.28 Finally,
as Nbs can be genetically fused to other proteins, it should be
possible to present them on the cell membrane of a producer cell
line; thus, generating LVs that incorporate a cell-speciﬁc Nb in
their envelope during budding as described above. We previously
raised several Nbs against mouse bone marrow-derived DCs.29 Of
these, Nb DC2.1 was shown to target in vitro generated immature
and mature DCs, as well as macrophages.29 Therefore, this Nb was
used in the present study to develop the Nb display technology
and deliver a proof-of-principle on the use of Nbs to target LVs to
speciﬁc cell types of mouse and human origin.
RESULTS
The Nb display technology allows production of high titer LVs
In this study, we developed a strategy based on the advantageous
characteristics of LVs and Nbs to transductionally target LVs to
speciﬁc cell types. This innovative strategy is called the Nb display
technology. Herein recognition of the target cell and subsequent
fusion of the target cell membrane with the viral membrane are
mediated by two separate proteins, the Nb and VSV.GS,30
respectively. As we are interested in exploiting LVs for immuno-
therapeutic purposes and since we previously identiﬁed Nb DC2.1
as a Nb that speciﬁcally binds APCs, in particular DCs and
macrophages, we decided to use this Nb to establish a proof-of-
concept.29 As a negative control we used Nb BCII10, which binds
to subunit 10 of the b-lactamase BcII enzyme of Bacillus cereus.31
First, we evaluated whether this approach allows the production
of LVs with high stability, hence, high titer, as this is a minimal pre-
requisite to use LVs for in situ transduction of target cells, such as
APCs. To that end, the production of LVs displaying Nb and VSV.GS
was compared with the production of VSV.G pseudotyped LVs, as
the latter are considered the standard for comparison.32 To do this
producer cells stably expressing Nb DC2.1 or BCII10 on their cell
membrane were generated. Therefore, human embryonic kidney
cells (HEK) 293T cells were transduced with LVs encoding
membrane bound Nb DC2.1 or BCII10, respectively. These cells
were used to generate VSV.GS pseudotyped LVs. Non-modiﬁed
HEK 293T cells were used to generate VSV.G pseudotyped LVs. We
compared the transfection of Nb expressing versus non-modiﬁed
HEK 293T cells by ﬂow cytometry (Figure 1a and Supplementary
Figure 2, n¼ 6), demonstrating high expression of the transgene
(Thy1.1 or tNGFR) on all transfected HEK 293T cells, as well as high
expression of the Nbs (myc tag) on Nb-modiﬁed HEK 293T cells.
Next, we measured the reverse transcriptase (RT) content of the
LVs (Figure 1b), demonstrating high levels of RT in the LV
preparations. Comparison of the RT content with the titer as
determined in ﬂow cytometry of VSV.G pseudotyped LVs revealed
that 1 ng RT correlated with 2.5 104 TU (transducing units),
demonstrating that the titers obtained for Nb displaying LVs are
suitable for in vivo applications (n¼ 6). To verify the presence of
the Nbs on the LV particles, we ﬁrst performed an ELISA in which
an anti-VHH antibody was used to capture the Nb displaying LVs,
after which binding of these LVs was demonstrated using an anti-
Thy1.1 detection antibody (Figure 1c, n¼ 3). As a ﬁnal quality
control, we performed western blot on known amounts of LVs
(5 ng RT) to assess the amount of VSV.GS and Nbs in the viral
preparations. To that end, we used an anti-hemagglutinin A (HA)
antibody, which binds to the HA tag present within both the
VSV.GS and Nb (Figure 1d, n¼ 4). We moreover determined the
density of the western blot signals in order to determine the ratio
of Nbs versus VSV.GS, demonstrating that this ratio was not only
stable intra-, but also inter LV preparations (Figure 1e, n¼ 4).
LVs displaying Nb DC2.1 target mouse APCs
On the basis of the knowledge that Nb DC2.1 binds speciﬁcally to
mouse DCs and macrophages, we hypothesized that unlike VSV.G
pseudotyped LVs, Nb DC2.1 displaying LVs should exclusively
transduce DCs and macrophages.29 To evaluate this hypothesis,
we ﬁrst transduced mouse ﬁbroblasts (NIH 3T3), T (EL4 cells) and
B (A20 cells) cells, macrophages (RAW246.7 cells) and bone
marrow-derived DCs in vitro with VSV.G pseudotyped or Nb BCII10
or DC2.1-displaying LVs encoding Thy1.1 at multiplicity of
infection 10. Flow cytometry was performed 72 h after transduc-
tion and demonstrated Thy1.1 expression in all cell types upon
transduction with VSV.G pseudotyped LVs. In contrast, none of the
cell types evaluated were transduced when incubated with BCII10
displaying LVs. More importantly, upon transduction with Nb
DC2.1 displaying LVs, we observed Thy1.1 expression by DCs and
macrophages, but not by ﬁbroblasts, B or T cells (Figure 2a and
Supplementary Figure 3, n¼ 3). We furthermore demonstrated
that the observed transduction was Nb-mediated, as pre-incuba-
tion of in vitro generated DCs with an excess of Nb DC 2.1, but not
Nb BCII10, abrogated their transduction by Nb DC2.1 displaying
LVs (Figure 2b, n¼ 2).
As our main goal is to use targeted LVs for in situmodiﬁcation of
cells, we next evaluated the speciﬁcity of the Nb DC2.1 displaying
LVs in vivo. As Nb DC2.1 targets LVs to APCs in vitro, we decided to
deliver the targeted LVs to the inguinal lymph node (LN) of C57BL/
6 mice, as LNs have a relative high concentration of both DCs and
macrophages.33 - 35 First, we administered LVs (105 TU) encoding
FLuc. Thirty-six hours later, in situ transduction was evaluated
using in vivo bioluminescence imaging (Figure 2c), demonstrating
luminescence when VSV.G pseudotyped or Nb DC2.1 displaying
LVs were administered, but not when Nb BCII10 displaying LVs
were administered (n¼ 3). We next performed a nested PCR on
genomic DNA isolated from these LNs, conﬁrming that absence of
luminescence upon delivery of Nb BCII10 displaying LVs was truly
because of the lack of transduction and that the luminescence
observed with VSV.G pseudotyped and Nb DC2.1 displaying LVs
was owing to genuine transduction (Figure 2d, n¼ 3). These data
demonstrate that Nb DC2.1 displaying LVs transduce cells in situ,
however, they do not indicate speciﬁcity. Therefore, C57BL/6 mice
with a Thy1.2 background were injected in the inguinal LN with
106 TU of LVs encoding Thy1.1. Thirty-six hours later, LNs were
isolated, reduced to a single cell suspension and characterized.
Cells were stained with an anti-Thy1.1 antibody in combination
with antibodies against CD11b and F4/80, CD11c and CD8a,
CD11c and B220, CD3 or CD19 to evaluate Thy1.1 expression by
macrophages, conventional DCs (cDCs), plasmacytoid DCs (pDCs),
T or B cells, respectively (Figure 2e, n¼ 3). Flow cytometry
demonstrated a similar transduction pattern of the evaluated LVs
as observed in vitro, that is, VSV.G pseudotyped LVs transduced all
cell types evaluated, whereas Nb BCII10 displaying LVs transduced
none. More importantly, Nb DC2.1 displaying LVs were transduc-
tionally targeted to macrophages, cDCs and pDCs. Moreover, the
transduction of cDCs, which are thought to mediate immune
responses upon LV transduction, was enhanced when targeted
LVs were used when compared with VSV.G pseudotyped LVs
(Figure 2f and Supplementary Figure 4, n¼ 3).
LVs displaying Nb DC2.1 target human APCs
The experiments described above demonstrate efﬁcient gene
delivery to APCs in vivo. This greatly enhances the therapeutic
potential of LV-based immunotherapeutic strategies as targeting
reduces the risk of insertional mutagenesis and off-target effects.
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However, to translate this strategy to the clinic, targeting of
human APCs has to be evaluated. As it was demonstrated that
Nb DC2.1 also binds human APCs (data not shown), we next
translated the mouse data described above to a human model.
First, we transduced in vitro cultured human ﬁbroblasts, mono-
cyte-derived macrophages and DCs, as well as blood-derived
B and T cells with Thy1.1 encoding LVs at an multiplicity of
infection of 10. Flow cytometry performed 72 h later demon-
strated that the DC2.1 displaying LVs speciﬁcally targeted human
DCs and macrophages, whereas Nb BCII10 displaying LVs did not;
VSV.G pseudotyped LVs again transduced all cell types evaluated
(Figure 3a and Supplementary Figure 5, n¼ 3). Next, we generated
single cell suspensions of human LNs and transduced these cells
with Thy1.1 encoding LVs. Thirty-six hours later, the cells were
stained for Thy1.1, as well as CD14 and CD11b, CD11c and BDCA-3,
CD123 and BDCA-2, CD3 or CD19, to evaluate Thy1.1 expression
by macrophages, myeloid DCs, pDCs, T cells or B cells, respectively
(Figure 3b, n¼ 3). These experiments demonstrate that VSV.G
pseudotyped LVs transduced all cell types evaluated, whereas Nb
BCII10 displaying LVs did not. Importantly, selective transduction
of macrophages, myeloid DCs and pDCs was observed upon
transduction with DC2.1 displaying LVs (Figure 3c and Supple-
mentary Figure 6, n¼ 3). Comparable to what was observed in
mice, Nb DC2.1 displaying LVs appeared to transduce myeloid DCs
more efﬁciently when compared with macrophages and pDCs,
whereas VSV.G pseudotyped LVs transduced these cell types at
equal efﬁciency. These data demonstrate that the Nb display
technology can be applied to target human APCs.
DISCUSSION
Several vaccination strategies with great potential have been
developed to treat diseases, such as cancers, chronic infections
and autoimmune disorders. One of these is the use of LVs to
deliver cancer, viral or autoimmune antigens together with
immune-modulating molecules to APCs, which subsequently
induce the appropriate immune response, that is, immunity or
tolerance, respectively.36 Optimization of the safety and efﬁciency
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Figure 1. Production of Nb displaying LVs. (a) Non-modified HEK 293T cells or HEK 293T cells stably expressing Nb BCII10 or DC2.1 were
used to produce LVs pseudotyped with VSV.G or VSV.GS, respectively. Three days after transfection of these cells with the VSV.G or VSV.GS,
gag/pol and transgene encoding plasmids, we evaluated the expression of the transgene (Thy1.1 or tNGFR), as well as the Nb (myc tag) by
flow cytometry. Non-transfected HEK 293T cells served as a control. The flow cytometry dot plots demonstrate high expression of the
transgene (y axis) in all transfected cells (VSV.G, BCII10 and DC2.1) and high expression of Nbs (x-axis) on the Nb-modified HEK 293T
cells (BCII10 and DC2.1). One representative experiment is shown (n¼ 6). (b) To compare the LV preparations we determined their RT content.
The graph depicts the amount of RT (ng RT/ml) in the LV preparations. Each dot represents one LV stock, the horizontal line shows the mean
(n¼ 6). (c) An ELISA involving anti-VHH and anti-Thy1.1 as capture and detection antibodies, respectively, was used to demonstrate the
incorporation of Nbs into the surface of Thy1.1 encoding LVs. A serial dilution of LVs was applied (5, 2.5 and 1.25 ng RT). The graph depicts the
OD-values detected. One representative experiment is shown (n¼ 3). (d) Western blot was performed as a quality control of the LVs.
After separation on a 15% sodium dodecyl sulphate-polyacrylamide gel and transfer to a nitrocellulose membrane, the Nbs (±25 kDa) and
VSV.GS (±15 kDa), which both contain an HA epitope tag, were detected with an anti-HA antibody. One representative experiment is shown
(n¼ 4). (e) The density of the western blot signals was determined using the Photocapt MW software and used to determine the ratio of Nbs/
VSV.GS on the LVs. This ratio is shown in the graph, in which each dot represents one LV stock and the horizontal line shows the mean (n¼ 4).
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of the LVs used to modify APCs could make them an even more
powerful tool for developing novel treatment modalities against
various diseases.
In this report, we present the Nb display technology to generate
LVs targeted to APCs. This approach exploits the natural budding
mechanism of LVs to incorporate a binding-defective, but fusion-
competent envelope glycoprotein derived from VSV.G30 together
with a membrane bound APC-speciﬁc Nb. To our knowledge,
there have been no prior reports on the use of Nbs for targeting of
LVs. Furthermore, we are the ﬁrst to demonstrate (1) production of
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high titer APC-targeted LVs, (2) conﬁrmation of in vivo transduc-
tion of LN cells upon delivery of targeted LVs by in vivo
bioluminescence imaging and (3) speciﬁc transduction of human
LN DCs and macrophages.
Production of LVs at a high titer is a pre-requisite for their
application in vivo. As, we wanted to compare the titers of broad
tropism LVs to those of Nb displaying LVs, we ﬁrst generated Nb-
expressing producer cells. As a consequence, the LV production
was based on the classical three-plasmid transfection for both LV
types. We observed no cytotoxicity because of the expression of
Nbs on the producer cells, which underscores the suitability of Nbs
as small non-toxic molecules for incorporation on LVs. Further-
more, we demonstrate that the Nb-expressing cell lines allow the
production of LVs at similar titers as VSV.G pseudotyped LVs, the
LV type against which other LVs are compared.32 The ability to
generate LVs at high titers is an important advantage of our
Figure 2. Selective transduction of mouse DCs and macrophages by Nb DC2.1 displaying LVs. (a) Mouse NIH 3T3 fibroblasts, A20 B lymphoma
and EL4 T lymphoma cells, RAW 264.7 macrophages and bone marrow-derived DCs were mock transduced or transduced with VSV.G
pseudotyped or Nb BCII10 or DC2.1 displaying LVs (multiplicity of infection 10). Flow cytometry was performed 72 h later to evaluate
transgene, Thy1.1, expression. The histograms demonstrate Thy1.1 positivity in the evaluated cell types. The tinted, blue, black and red
histogram, represent mock transduced cells or cells transduced with Nb BCII10 displaying LVs, VSV.G pseudotyped LVs or Nb DC2.1 displaying
LVs, respectively. One representative experiment is shown (n¼ 3). (b) Mouse bone marrow-derived DCs were pre-incubated with an excess of
Nb BCII10 or DC 2.1, after which these were transduced with Thy1.1 encoding LVs displaying the respective Nbs. Expression of Thy1.1 was
determined 72 h later. The dot plots demonstrate the Thy1.1 expression by DCs upon mock transduction (control), transduction with VSV.G
pseudotyped LVs, LVs displaying Nb BCII10 or DC2.1 when pre-incubated with Nb BCII10 or DC2.1. One representative experiment is shown
(n¼ 2). (c) To evaluate the targeting strategy in vivo, we first administered 105 TU of FLuc encoding LVs to the inguinal LN of C57BL/6 mice.
In vivo bioluminescence imaging was performed 36 h later to obtain bioluminescent pseudo-color images, in which high luminescence
(a measure for the amount of FLuc positive cells) is shown in red and weak luminescence in blue. The color scale underneath the images
represents the LUT or Look up Table, and correlates the luminescence to an absolute amount of counts (light units). The pseudo-color images
were superimposed on gray-scale photographs of the mice (n¼ 3). (d) To confirm transduction, hence, proviral integration in the genome of
LN cells, we performed a nested PCR on the genomic DNA isolated from these LNs. Subsequently, the PCR fragments were separated using a
1.2% agarose gel. Lanes 1 --7 depict the 1 kb DNA ladder, water control of the first (W1) and second (W2) PCR, and the PCR amplification
products of genomic DNA isolated from LNs injected with VSVG pseudotyped LVs or LVs pseudotyped with VSV.GS and displaying Nb BCII10
or DC2.1 (n¼ 3). (e, f ) LVs encoding Thy1.1 were administered (106 TU) to the inguinal LN in order to track LV transduced cells. Analyses were
performed 36h later on single cell suspensions prepared from these LNs. In order to evaluate Thy1.1 expression in macrophages, myeloid DCs
and lymphoid DCs (together conventional DCs), pDCs, B and T cells the LN cells were stained with the antibody directed against Thy1.1 in
combination with antibodies directed against CD11b F4/80, CD11c CD8a, CD11c CD8a, CD11c B220, CD19 and CD3, respectively. The
dot plots in (e) depict the cell populations of which the Thy1.1 expression is shown in the graphs in (f ). One representative experiment
is shown (n¼ 3).
T cells B cellsmacrophages DCsfibroblasts
%
 o
f M
ax
mock
VSV.G
BCII10
DC2.1
Thy1.1
T cells B cellsplasmacytoid DCs
plasmacytoid DCs
B
D
CA
3
B
D
CA
2
CD
14
SS
C-
H
SS
C-
H
CD11c CD123CD11b CD3 CD19
T cells B cells
%
 o
f M
ax
mock
VSV.G
BCII10
DC2.1
Thy1.1
macrophages
macrophages
myeloid DCs
myeloid DCs
9% 0.5% 1.5% 65% 26%
Figure 3. Selective transduction of human DCs and macrophages by DC2.1 displaying LVs. (a) Human fibroblasts, blood-derived B and T cells,
in vitro generated macrophages and bone marrow-derived DCs were mock transduced or transduced with VSV.G pseudotyped, or Nb BCII10
or DC2.1 displaying LVs (multiplicity of infection 10). Flow cytometry was performed 72h later to evaluate transgene (Thy1.1) expression. The
histograms demonstrate Thy1.1 positivity in the evaluated cell types. The tinted, blue, black and red histogram, represent mock transduced
cells or cells transduced with Nb BCII10 displaying LVs, VSV.G pseudotyped LVs and Nb DC2.1 displaying LVs, respectively. One representative
experiment is shown (n¼ 3). (b, c) Single cell suspensions prepared from human LNs were transduced in vitro with Thy1.1 encoding LVs
(multiplicity of infection 10). In order to evaluate Thy1.1 expression in macrophages, myeloid DCs, pDCss, B and T cells, these cells were
co-stained with the anti-Thy1.1 antibody and antibodies directed against CD11b CD14, CD11c BDCA-3, CD123 BDCA-2, CD19 and CD3,
respectively. The flow cytometry graphs in panel C depict Thy1.1 expression; the corresponding cell populations are shown in the histograms
displayed in panel (b). The tinted, blue, black and red histogram represent, mock transduced cells or cells transduced with Nb BCII10
displaying LVs, VSV.G pseudotyped LVs or Nb DC2.1 displaying LVs, respectively. One representative experiment is shown (n¼ 3).
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strategy. Although the group of Funke et al.37 was able to improve
both titer and selectivity by pseudotyping LVs with wild-type
measles virus glycoproteins, most alternative strategies don’t
report on this phenomenon. In general, titers and speciﬁcity of
pseudotypes, including N-terminal insertion of MHC II-speciﬁc
scFv20 to the VSV.G, murine leukemia virus-A21 or mutated
measles virus H-protein,22 or the use of a modiﬁed Sindbis virus
envelope glycoprotein,23 were lower compared with those of the
Nb displaying LVs described in this study.
To address the transduction speciﬁcity, we evaluated the
transduction proﬁle of Nb DC2.1 displaying LVs on mouse as well
as human APCs. We conﬁrmed Nb-dependent and APC-speciﬁc
transduction of Nb DC2.1 displaying LVs on murine cell lines and
in vitro generated DCs. We showed in vivo transduction with the
Nb DC2.1 displaying LVs after intranodal injection using in vivo
bioluminescence imaging and conﬁrmed these results by nested
PCR. Although in vivo bioluminescence imaging has been
previously applied to prove speciﬁc transduction of tumor cells,38
we are the ﬁrst to report on successful bioluminescent images of
in vivo transduced APCs with targeted LVs. Previous attempts to
evidence targeted APC transduction in vivo were made by
subcutaneous injection of FLuc encoding LVs. The lack of
luminescence in these experiments was ascribed to the sparse
distribution of skin-derived DCs, which was beyond the sensitivity
of the applied imaging method.23 Phenotypic characterization of
the in situ transduced LN cells demonstrated that the entry of Nb
DC2.1 displaying LVs was limited to macrophages, cDCs and pDCs.
Importantly, the transduction of myeloid DCs, which are thought
to mediate immune responses upon LV transduction,1 was
enhanced when these targeted LVs were used.
Selective transduction of DC2.1 displaying LVs was moreover
evidenced on human in vitro generated APCs, as we demonstrated
transduction of macrophages and DCs, but not ﬁbroblasts, B or T
cells. More importantly, we were able to conﬁrm these data on
human LN-derived cells. This may facilitate translation of the data
obtained in mice to a relevant human model. Interestingly, similar
to the mouse data, Nb DC2.1-displaying LVs were more efﬁcient in
transducing human myeloid DCs than human macrophages or
pDCs. The difference in transduction efﬁcacy of the Nb displaying
LVs can be interpreted in several ways. First, binding of the Nb-
displaying LVs and their subsequent fusion with the target cell
membrane are mediated by two different molecules, a binding Nb
and a fusogenic VSV.GS molecule, which is opposed to only one
protein (VSV.G) in broad tropism LVs. However, this also holds true
for LVs pseudotyped with the measles virus envelope glycoprotein
for which several groups reported on high transduction
efﬁcacy.18,19,22,37 Alternatively, the reduced transduction efﬁcacy
can be explained by the binding process of the LVs on the target
cell. Most cells heavily express the receptor to which VSV.G
binds,39 whereas the expression of the antigen, recognized by Nb
DC2.1, is limited to DCs and macrophages. Moreover, the identity
of this antigen is unknown. We can’t exclude variation in the
expression of the antigen depending on the DC and macrophage
subtype and its activation status. The successful work of several
groups targeting CD20 or MCH II is suggestive for this hypothesis
as these molecules are highly expressed on the respective target
cells.20 - 22,40 The latter explanation is not detrimental to the
proposed work, but indicates that it is critical to identify the best
target antigen and binding Nb with regard to targeting.
It will be critically important to extend the current pre-clinical
studies applying targetable LVs into an off-the-shelf immuno-
therapy approach for clinical applications. We believe that the
described approach provides an important step toward this goal
as it tackles major concerns such as off-target transduction and
the risk on insertional mutagenesis.41 We believe that the latter is
severely reduced with our approach as APCs are cells with a
relatively short life span, and as transformation is a multistep
process,42 oncogenesis is unlikely to occur.
Finally, one of the major advantages of this system is that it can
be easily applied to target different cell types. As mentioned in the
introduction the generation, selection and molecular cloning of
Nbs is straightforward. Moreover, Nbs can be generated against
any cell type without the need for prior knowledge of a cell-
speciﬁc marker, which can be a challenge in itself. Consequently,
the Nb display technology further enhances the potential of LVs as
a widely used gene delivery vehicle for fundamental research,
functional genomics and gene therapy purposes.
MATERIALS AND METHODS
Mice, human LNs and cell cultures
Six to 12-week-old C57BL/6 female mice (Thy1.2) were purchased from
Harlan (Horst, The Netherlands). Animals were handled according to the
institutional guidelines and experiments were approved by the Ethical
Committee for use of laboratory animals of the VUB (Protocol no 10-214-1,
date 31-03-2010). Approval to use LNs from organ donors was obtained
from the institutional review board (Protocol no BUN14320108848, date
26-06-2010).
HEK 293T, NIH 3T3 cells (mouse ﬁbroblasts), RAW264.7 cells (mouse leukemic
macrophage cell line), EL4 cells (mouse T-lymphoma cell line) and A20 cells
(mouse B-lymphoma cell line) were cultured as recommended by the American
Type Culture Collection (ATCC, Rockville, MD, USA). The generation of mouse
bone marrow-derived and human monocyte-derived DCs, as well as the
isolation of B and T cells from peripheral blood was performed as previously
described.5 Monocytes were selected by adherence and cultured in the
presence of M-CSF in order to generate human macrophages.
Single cell suspensions were prepared from murine and human LNs. For
the latter, the procedure described for preparation of single cell
suspensions from mouse LNs was adapted.8 Brieﬂy, human LNs were
injected with phosphate buffered saline (Lonza, Verviers, Belgium)
containing Collagenase III (100Uml1, Sigma-Aldrich, Bornem, Belgium)
and DNase I (32.5 Uml1, Sigma-Aldrich). The LNs were immersed in 500ml
of phosphate buffered saline containing 0.5% human AB serum (PAA
Laboratories, Linz, Austria) and incubated at 37 1C, 5% CO2 for 30min,
after which they were tamped with a plunger of a 3-cc syringe.
A single cell suspension was obtained by passing the cells through a
70-mm cell strainer on a 15-ml tube. The cells were cultured at 1 106 cells
ml1 in X-VIVO 15 medium (BioWhittaker, Walkersville, MD, USA) containing
1% human AB serum.
LV production
Plasmids. The packaging plasmid pCMVDR8.9 and VSV.G encoding
plasmid pMD.G were a gift from Dr D Trono (University of Geneva). The
plasmid pUB6-VSV.GS, which encodes the binding-defective, but fusion-
competent VSV.G was described by Zhang et al.30 The VSV.GS is schematically
represented in Supplementary Figure 1A. The plasmids encoding Thy1.1
(pSIN-Thy1.1) or Fireﬂy Luciferase (FLuc, pHR trip CMV luc2-Ires-tNGFR SIN)
were previously described.8 The sequence encoding Nb BCII10 or DC2.129
was cloned into the phage display vector, pHEN6c as a NcoI-Eco91I (BstEII)
fragment. Subsequently the cloning sites SacII and SalI were introduced in
the Nb sequence by PCR, after which the Nbs were cloned as a SacII-SalI
fragment in the vector pDISPLAY (Invitrogen, Paisley, UK), resulting in
pDISPLAY-Nb BCII10 and pDISPLAY-Nb DC2.1. As a consequence, the Nb-
encoding sequence is fused at the N-terminus to the mouse Igk chain leader
sequence and at the C-terminus to the platelet derived growth factor
receptor transmembrane domain, to direct the Nb to the secretory pathway
and subsequently anchor it to the plasma membrane. The Nbs expressed
from this vector further contain the HA and myc epitopes (used for western
blot and ﬂow cytometry, respectively). A PCR to introduce the SpeI and EcoRI
cloning sites into the membrane bound version of Nb BCII10 and DC2.1 was
performed, after which this fragment was cloned into the backbone pHR’
vector, using these restriction sites.5
Virus production. In order to prepare LVs, HEK 293T cells were plated at
15 106 cells per 175 cm2. These were transfected the following day using
Nanobody display technology
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polyethyleneimine (Polysciences, Eppelheim, Germany) with 15, 30 and
45mg of the envelope, gag/pol and transgene encoding plasmids,
respectively. LV-containing supernatant was collected the following 3
days and concentrated by ultracentrifugation (1000 g) as previously
described.5
Virus characterization. The colorimetric RT assay (Roche, Vilvoorde,
Germany) was used to determine the amount of RT in the concentrated LV
preparation.43 Comparison of the RT content with the titer, as determined
in ﬂow cytometry, of VSV.G pseudotyped LVs revealed that 1 ng RT
correlated with 2.5 104 TU. ELISA was performed following standard
procedures using an anti-VHH and an anti-Thy1.1 antibody (Becton
Dickinson, BD, Regenbogen, Belgium) as capture and detection antibody,
respectively. Western blot was performed on LVs (5 ng RT). Viral proteins
were separated on a 15% sodium dodecyl sulfate-polyacrylamide gel,
transferred to a nitrocellulose membrane, after which Nbs and VSV.GS,
which contain an HA tag, were detected with an anti-HA antibody (Sigma-
Aldrich) and a horseradish peroxidase-conjugated goat anti-mouse IgG
antibody (Santa Cruz Biotechnology, Heidelberg, Germany) as primary and
secondary antibody, respectively. The signal density was measured using
the Photocapt MW software (Vilber Lourmat, Marne-La-Vallee, France) to
determine the ratio between Nbs and VSV.GS on LVs.
Transduction of cells
In vitro transduction of mouse and human ﬁbroblasts, DCs, macrophages,
B and T cells, as well as LN cells, was performed at a multiplicity of infection
of 10 as previously described.5 To achieve transduction of cells in situ the
inguinal LN of C57BL/6 mice was injected with 105 - 106 TU of LVs
resuspended in 10ml phosphate buffered saline containing 10mgml1
protamine sulphate (LeoPharma, Lier, Belgium). Analyses of in vitro
transduced cells was performed 36 (primary cells) or 72 h (cell lines and
in vitro generated DCs) after transduction, whereas analyses of in vivo
transduced cells was performed 36h after LV injection.
In vivo bioluminescence imaging
In vivo bioluminescence imaging was performed as previously described to
visualize in situ transduction of LN cells by FLuc encoding LVs.8,44
Nested PCR
Genomic DNA was isolated from LNs injected with FLuc encoding LVs
using the QIAamp DNA mini kit (Qiagen, Antwerpen, Belgium). Integrated
pro-viruses were detected by nested PCR. The initial PCR was performed
on 500 ng of genomic DNA with the forward primer (CPPT 8951) 50-A
GGGGAAAGAATAGTAGACAT-30 and reverse primer (B2) 50-ATATGTAA
GTACACTGTAGC-30 , using a hot start polymerase mix (Kapa Biosystems,
Eke, Belgium) and the following PCR program 95 1C 50 , 35 (95 1C 1500 ,
60 1C 1500 , 72 1C 3000), 72 1C 70 and hold at 4 1C. The second PCR was
performed on 1 ml of the ﬁrst PCR reaction with the forward primer (CMV
9551) 50-CAAATGGGCGGTAGGCGTGTA-30 and reverse primer (Lenti Rev)
50-CCTTGTAA GTCATT GGTCCTTAA-30 , using the same enzyme and PCR
program.
In vivo tracking of LVs
To evaluate transduction of LN cells by Thy1.1 encoding LVs, mice were
killed, the injected LN isolated, after which a single cell suspension was
prepared using Liberase TL (Roche). Cells were characterized in ﬂow
cytometry.
Flow cytometry
Staining of surface markers was performed as previously described.5 A
biotinylated anti-myc antibody (Millipore, Brussels, Belgium) was used to
assess the expression of Nbs on Nb modiﬁed HEK 293T cells. Phycoerythrin
conjugated anti-Thy1.1 (Biolegend, ImTec Diagnostics, Antwerpen,
Belgium) or anti-NGFR (BD) antibodies were used to evaluate transgene
expression in modiﬁed cells. Mouse cells were characterized using:
allophycocyanin conjugated antibodies against CD11c (BD) and CD19
(Biolegend), ﬂuorescein isothiocyanate conjugated antibodies against
CD11b (BD), peridinin - chlorophyll proteins-Cy5.5 (PerCP-Cy5.5) conju-
gated antibody against CD8aBD and biotinylated antibodies against F4/80,
CD3 and B220 (made in house). Human cells were further characterized
using: APC conjugated antibodies against CD11c (BD), CD19 (BD) and
CD123 (BD); ﬂuorescein isothiocyanate conjugated antibodies against
CD14 (BD) and CD3 (BD); PerCP-Cy5.5 conjugated antibodies against
CD11b (BD) and biotinylated antibodies against BDCA-3 and BDCA-2
(Miltenyi Biotec, Leiden, The Netherlands). Biotinylated antibodies were
detected with a streptavidin-PerCP-Cy5.5 (BD). Data were collected using a
FACSCanto ﬂow cytometer (BD) and analyzed using FACSDiva (BD) or
FlowJo software (Tree Star, Inc., Ashland, OR, USA).
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